Article Sidebar
Views PDF: 0
PRELIMINARY STUDY ON PLASMA sTNFR1 LEVELS IN TYPE 2 DIABETES MELLITUS PATIENTS WITH CHRONIC KIDNEY DISEASE AT HANOI NEPHROLOGY HOSPITAL
Main Article Content
Abstract
Objective: To evaluate plasma sTNFR1 concentration and its association with the degree of renal damage in patients with chronic kidney disease on the basis of type 2 diabetes. Methods: Cross-sectional study on 80 type 2 diabetic patients examined as outpatients at Hanoi Kidney Hospital from July 2024 to May 2025, divided into 4 groups: Group 0 (no CKD, n=22), Group 1 (stage 1-2, n=20), Group 2 (stage 3, n=22), Group 3 (stage 4, n=16). sTNFR1 was quantified by ELISA. Clinical and paraclinical indices (urea, creatinine, eGFR, proteinuria, microalbuminuria) were collected. Results: sTNFR1 levels increased gradually according to CKD stage (2.612; 2.601; 5.073; 7.698 ng/mL, p<0.01). sTNFR1 was positively correlated with urea (rho=0.516), creatinine (rho=0.744), proteinuria (rho=0.477), microalbuminuria (rho=0.407); inversely correlated with eGFR (r=-0.799) and serum albumin (rho=-0.305) (p<0.05). Logistic regression showed that sTNFR1 was an independent predictor of eGFR <60 ml/min/1.73 m² (OR=3.177 per 1 ng/mL increase, p<0.001). ROC analysis confirmed high diagnostic value (AUC=0.907; 95% CI: 0.838-0.977; p<0.0001). Conclusion: sTNFR1 is a potential biomarker reflecting kidney damage, supporting early detection, risk stratification and monitoring of CKD progression in patients with type 2 diabetes.
Article Details
Keywords
sTNFR1, chronic kidney disease, type 2 diabetes mellitus.
References
2. Uma A, Sivaraman S, Manoharan R, Periasamy P. Diabetic Kidney Disease in Type 2 Diabetes: A Comprehensive Review of Epidemiology, Pathophysiology, and Therapeutic Advances. J Pharm Bioallied Sci. 2025 Apr-Jun;17(2):33-35.
3. P. E. Stevens et al., KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease, Kidney Int., vol. 105, no. 4, pp. S117–S314, Apr. 2024.
4. Afkarian M, Sachs MC, Kestenbaum B, et al. Kidney disease and increased mortality risk in type 2 diabetes. J Am Soc Nephrol. 2013;24(2): 302-308.
5. Tsalamandris S, Antonopoulos AS, Oikonomou E, et al. The Role of Inflammation in Diabetes: Current Concepts and Future Perspectives. Eur Cardiol Rev. 2019;14(1):50-59.
6. Awad AS, You H, Gao T, et al. Macrophage-derived tumor necrosis factor-α mediates diabetic renal injury. Kidney Int. 2015;88(4):722-733.
7. A. C. Carlsson et al., Association of Soluble Tumor Necrosis Factor Receptors 1 and 2 with Nephropathy, Cardiovascular Events, and Total Mortality in Type 2 Diabetes, Cardiovasc. Diabetol., vol. 15, p. 40, Feb. 2016.
8. N. Gómez-Banoy, V. Cuevas, A. Higuita, L. H. Aranzález, and I. Mockus, Soluble tumor necrosis factor receptor 1 is associated with diminished estimated glomerular filtration rate in colombian patients with type 2 diabetes, J. Diabetes Complications, vol. 30, no. 5, pp. 852–857, Jul. 2016.
9. Kerry Willis, PhD, Senior Vice-President for Scientific Activities Michael Cheung, MA, Guideline Development Director Sean Slifer, BA, Guideline Development Manager.Kidney international supplements.Official journal of the international society of nephrology.Volume 3, Issue 3,November 2013.
10. Niewczas MA, Ficociello LH, Johnson AC, Walker W, Rosolowsky ET, Roshan B, Warram JH, Krolewski AS. Serum concentrations of markers of TNFalpha and Fas-mediated pathways and renal function in nonproteinuric patients with type 1 diabetes. Clin J Am Soc Nephrol. 2009 Jan;4(1):62-70.